Thursday, August 08, 2024 4:39:39 PM
Wait for me maybe buy back in lol....if things go OK with other stock
always been bullish on Bucy but management lol...Ops
Not sure ...
Like this...
Not sure ...
Like this...
That is BS. The FDA is a joke, but the reason Buci failed was because of a poor trial design which included the lack of tracking symptoms resolution. RVVTF and the trial designer’s are solely at fault. No doubt that Buci works; the ball was fumbled at the goal line.
— Hattrick7 (@Hattrick710) May 8, 2024
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
